Sorin Group announced the results of the DREAM clinical trial. In this study, the sleep apnea monitoring (SAM) algorithm of Sorin Reply 200 pacemakers was validated against polysomnography, the gold standard method used to measure the severity of sleep apnea (SA). Initial data show that Reply 200 with the new SAM algorithm provides reliable screening for the risk of severe SA[1].

Validating its shock reduction research and technology, Medtronic Inc. announced the results of three clinical trials, Shock-Less, PainFree SST and ADVANCE III, which successfully employed key strategies to dramatically reduce inappropriate and unnecessary shocks in patients with implantable cardiac defibrillators (ICD). The studies followed more than 7,000 patients on six continents; results were presented at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions.

Boston Scientific Formio Vitalio Inliven Pacemakers EP Lab

Boston Scientific Corporation is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient's overall heart failure status. Comprising of the Inliven cardiac resynchronization therapy pacemaker (CRT-P) that synchronizes the heart chambers, and the Vitalio and Formio pacing systems, the new family of devices offers clinicians a comprehensive set of tools for the management of heart failure and related comorbidities.

Digisonics will exhibit its No. 1 KLAS rated cardiology picture archive and communications system (PACS) and structured reporting solutions at this year’s American Society of Echocardiography (ASE) Scientific Sessions in Minneapolis, Minn. 

More than 54 companies will display their latest products and services at the American Society of Echocardiography’s (ASE) 24th Annual Scientific Sessions, planned for June 29-July 2 at the Minneapolis Convention Center in Minneapolis, Minn. This year, the conference theme is “a disease-based focus on the role of echocardiography in diagnosis and guiding therapy”. 

June 25, 2013 — Siemens Healthcare announced that the U.S. Food and Drug Administration (FDA) has cleared the Virtual Touch imaging ultrasound application, Siemens’ first commercially available implementation of Acoustic Radiation Force Impulse (ARFI) technology.

June 25, 2013 — Zoll Medical Corp. announced that a paper published in Critical Care Medicine reported the likelihood of achieving a return of spontaneous circulation (ROSC) after sudden cardiac arrest (SCA) is 62 percent greater when the AutoPulse noninvasive cardiac support pump is used to deliver CPR chest compressions.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now